Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Springer Science and Business Media LLC - Tập 107 Số 1 - Trang 103-111 - 2007
Agnés Fournier1, Franco Berrino2, Françoise Clavel‐Chapelon1
1Institut National de la Santé et de la Recherche Médicale ERI 20, Institut Gustave Roussy, 94805, Villejuif, France
2Department of Preventive and Predictive Medicine, Istituto Nazionale Tumori, 20138, Milan, Italy

Tóm tắt

Từ khóa


Tài liệu tham khảo

Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552–553

Stanczyk FZ (2003) All progestins are not created equal. Steroids 68:879–890

Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J (1998) Progestins and breast cancer. J Steroid Biochem Mol Biol 65:225–235

Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049–2058

Campagnoli C, Abba C, Ambroggio S, Peris C (2005) Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 97:441–450

Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059

Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81:339–344

Newcomb PA, Titus-Ernstoff L, Egan KM et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11:593–600

Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

Stahlberg C, Pedersen AT, Lynge E et al (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721–727

Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130–134

Ewertz M, Mellemkjaer L, Poulsen AH et al (2005) Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92:1293–1297

Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M (2006) Postmenopausal hormone therapy and breast cancer risk: the multiethnic cohort. Int J Cancer 118:1285–1291

Hickey M, Davis SR, Sturdee DW (2005) Treatment of menopausal symptoms: what shall we do now? Lancet 366:409–421

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454

Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124

Weiss NS, Rossing MA (1996) Healthy screenee bias in epidemiologic studies of cancer incidence. Epidemiology 7:319–322

Santen RJ (2003) Risk of breast cancer with progestins: critical assessment of current data. Steroids 68:953–964

de Lignieres B (2002) Effects of progestogens on the postmenopausal breast. Climacteric 5:229–235

Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocr Rev 18:502–519

Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Mark CJ (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101:125–134

Muti P, Stanulla M, Micheli A et al (2000) Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes Control 11:721–730

Li CI (2004) Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas 49:44–50

Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920

Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 95:30–37